|
Psychotic Disorders
|
0.320 |
AlteredExpression
|
group |
BEFREE |
Expression of both Dlx1/2 and MR-GEF is retained in both adult mouse and human forebrain where, in human, decreased Dlx1 expression has been associated with psychosis.
|
20436929 |
2010 |
|
Nonorganic psychosis
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Expression of both Dlx1/2 and MR-GEF is retained in both adult mouse and human forebrain where, in human, decreased Dlx1 expression has been associated with psychosis.
|
20436929 |
2010 |
|
Psychotic Disorders
|
0.320 |
Biomarker
|
group |
BEFREE |
Patients with a history of psychosis showed significantly decreased relative numbers of DLX1-positive neurons compared with patients without history of psychosis and nonpsychiatric controls (P =.02), whereas no differences could be found in relative numbers of SHOX2-positive neurons (P>.15).
|
12963668 |
2003 |
|
Psychotic Disorders
|
0.320 |
Biomarker
|
group |
PSYGENET |
Patients with a history of psychosis showed significantly decreased relative numbers of DLX1-positive neurons compared with patients without history of psychosis and nonpsychiatric controls (P =.02), whereas no differences could be found in relative numbers of SHOX2-positive neurons (P>.15).
|
12963668 |
2003 |
|
Nonorganic psychosis
|
0.320 |
Biomarker
|
disease |
PSYGENET |
Patients with a history of psychosis showed significantly decreased relative numbers of DLX1-positive neurons compared with patients without history of psychosis and nonpsychiatric controls (P =.02), whereas no differences could be found in relative numbers of SHOX2-positive neurons (P>.15).
|
12963668 |
2003 |
|
Nonorganic psychosis
|
0.320 |
Biomarker
|
disease |
BEFREE |
Patients with a history of psychosis showed significantly decreased relative numbers of DLX1-positive neurons compared with patients without history of psychosis and nonpsychiatric controls (P =.02), whereas no differences could be found in relative numbers of SHOX2-positive neurons (P>.15).
|
12963668 |
2003 |
|
Autism Spectrum Disorders
|
0.310 |
Biomarker
|
disease |
CTD_human |
A rare haplotype in the DLX1 promoter was associated with ASD (P-value = 0.001).
|
21302352 |
2011 |
|
Autism Spectrum Disorders
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
A rare haplotype in the DLX1 promoter was associated with ASD (P-value = 0.001).
|
21302352 |
2011 |
|
Autistic Disorder
|
0.310 |
GeneticVariation
|
disease |
LHGDN |
We investigated 6 Tag SNPs within the DLX1/2 genes in two cohorts of multiplex (MPX) and one of simplex (SPX) families for association with autism.
|
18728693 |
2009 |
|
Autistic Disorder
|
0.310 |
Biomarker
|
disease |
CTD_human |
We investigated 6 Tag SNPs within the DLX1/2 genes in two cohorts of multiplex (MPX) and one of simplex (SPX) families for association with autism.
|
18728693 |
2009 |
|
Autistic Disorder
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
We investigated 6 Tag SNPs within the DLX1/2 genes in two cohorts of multiplex (MPX) and one of simplex (SPX) families for association with autism.
|
18728693 |
2009 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Relative numbers of DLX1- and SHOX2-positive neurons in patients with schizophrenia and bipolar disorder with history of psychosis compared with psychiatric and nonpsychiatric controls.
|
12963668 |
2003 |
|
Bipolar Disorder
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Decreased thalamic expression of DLX1 in schizophrenia and bipolar disorder with psychosis suggests shared genetic deficits in expression of this homeobox gene.
|
12963668 |
2003 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
BEFREE |
Relative numbers of DLX1- and SHOX2-positive neurons in patients with schizophrenia and bipolar disorder with history of psychosis compared with psychiatric and nonpsychiatric controls.
|
12963668 |
2003 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Relative numbers of DLX1- and SHOX2-positive neurons in patients with schizophrenia and bipolar disorder with history of psychosis compared with psychiatric and nonpsychiatric controls.
|
12963668 |
2003 |
|
Craniofacial Abnormalities
|
0.300 |
Biomarker
|
group |
CTD_human |
Role of the Dlx homeobox genes in proximodistal patterning of the branchial arches: mutations of Dlx-1, Dlx-2, and Dlx-1 and -2 alter morphogenesis of proximal skeletal and soft tissue structures derived from the first and second arches.
|
9187081 |
1997 |
|
Malignant neoplasm of prostate
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Urinary HOXC6 and DLX1 mRNA levels were quantified and RNA results were then combined with other risk factors in a clinical model optimized to detect ISUP (International Society of Urological Pathology) Grade Group 2 or greater prostate cancer in men with prostate specific antigen less than 10 ng/ml.
|
31026217 |
2019 |
|
Malignant neoplasm of prostate
|
0.070 |
Biomarker
|
disease |
BEFREE |
Similarly, urine-based biomarkers like prostate cancer antigen 3 (PCA3) and HOXC6/DLX1 have been shown to be more accurate than PSA screening.
|
30859272 |
2019 |
|
Malignant neoplasm of prostate
|
0.070 |
Biomarker
|
disease |
BEFREE |
In conclusion, the overexpression of miR-539-mediated DLX1 inhibition could potentially impede EMT, proliferation, migration and invasion of PCa cells through the blockade of the TGF-β/Smad4 signalling pathway, highlighting a potential miR-539/DLX1/TGF-β/Smad4 regulatory axis in the treatment of PCa.
|
31298493 |
2019 |
|
Prostate carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Similarly, urine-based biomarkers like prostate cancer antigen 3 (PCA3) and HOXC6/DLX1 have been shown to be more accurate than PSA screening.
|
30859272 |
2019 |
|
Prostate carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
In conclusion, the overexpression of miR-539-mediated DLX1 inhibition could potentially impede EMT, proliferation, migration and invasion of PCa cells through the blockade of the TGF-β/Smad4 signalling pathway, highlighting a potential miR-539/DLX1/TGF-β/Smad4 regulatory axis in the treatment of PCa.
|
31298493 |
2019 |
|
Prostate carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Urinary HOXC6 and DLX1 mRNA levels were quantified and RNA results were then combined with other risk factors in a clinical model optimized to detect ISUP (International Society of Urological Pathology) Grade Group 2 or greater prostate cancer in men with prostate specific antigen less than 10 ng/ml.
|
31026217 |
2019 |
|
Malignant neoplasm of prostate
|
0.070 |
Biomarker
|
disease |
BEFREE |
Taken together, this study demonstrated that DLX1 exerted the oncogenic roles on the prostate cancer by activating beta-catenin/TCF signaling.
|
29317218 |
2018 |
|
Prostate carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Taken together, this study demonstrated that DLX1 exerted the oncogenic roles on the prostate cancer by activating beta-catenin/TCF signaling.
|
29317218 |
2018 |
|
Malignant neoplasm of prostate
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Silencing of three genes (DLX1, PLA2G7 and RHOU) in the prostate cancer cell lines PC3 and VCaP by siRNA resulted in marked growth arrest and cytotoxicity, particularly in 3D organotypic cell culture conditions.
|
27196083 |
2016 |